

Right Heart Matters!

Date: 115 年 4 月 18 日(六) 13:30-16:30

Venue: 台南太子文旅 C 廳(臺南市東區大學路 2 號)

TIME	TOPICS	SPEAKER	MODERATOR
13:30-13:35 (5 mins)	Opening Remarks	心臟學會 林彥宏 主委	
13:35-13:55 (20 mins)	When Walking Becomes a Challenge: A PAH Patient Journey”	高長 心內 鍾昇穎 醫師	心臟學會 林彥宏 主委
	2026 PH guideline session		
13:55-14:15 (20 mins)	What’s new in 2026 TSOC PH guideline? Cardiologist perspective	高醫 心內 朱俊源 醫師	成大 心內 許志新 醫師
14:15-14:35 (20 mins)	What’s new in 2026 TSOC PH guideline? Rheumatologist perspective	高長 風濕 許鍾元 醫師	成大 風濕 翁孟玉 醫師
14:35-14:55 (20 mins)	PDE5i as the Cornerstone of Initial PAH Therapy	雲林臺大 心內 陳政璋 醫師	屏東 心內 鄭錦昌 醫師
14:55-15:05 (10 mins)	Panel discussion	心臟學會 肺高壓暨循環委員會 劉維新 副主委	
15:05-15:15 (10 mins)	Break	All	
	PH Young Investigator Forum		
15:15-15:35 (20 mins)	PH Case sharing - 1	成大 心內 林佳凌 醫師	高醫 心內 戴任恭 醫師
15:35-15:55 (20 mins)	PH Case sharing - 2	高榮 風濕 王愷君 醫師	高榮 風濕 呂聆音 醫師
15:55-16:15 (20 mins)	肺高壓心臟超音波小學堂	成大 心內 李文煌 醫師	心臟學會 劉維新副主委
16:15-16:25 (10 mins)	Panel discussion	風濕學會 歐燦騰 秘書長	
16:25-16:30 (5 mins)	Closing Remarks	風濕病醫學會 李克仁 理事長	

主辦單位: 社團法人中華民國心臟學會

What's new in TSOC PH guideline? Rheumatologist perspective

許鍾元 醫師 (高雄長庚風濕免疫科)

The 2026 TSOC Pulmonary Hypertension (PH) guidelines introduce critical shifts that directly impact our management of connective tissue disease-associated PAH (CTD-PAH). The lowered hemodynamic threshold (mPAP > 20 mmHg, PVR > 2 WU) means more Systemic Sclerosis (SSc) and SLE patients will cross the diagnostic line earlier. While cardiologists may advocate for the swift initiation of PAH-targeted therapies, we must critically evaluate the risk-benefit ratio. Premature exposure to costly vasodilators in multi-morbid CTD patients is not always the optimal first move.

Furthermore, the guideline's emphasis on multi-parameter screening mandates a proactive approach in our clinics. Relying solely on echocardiographic TR velocity is obsolete. We need a streamlined SOP integrating DLCO decline and NT-proBNP trends. Regarding the push for upfront combination therapy based on the four-tier risk stratification, we must assert our pharmacological expertise. CTD patients often have fluctuating renal and hepatic functions and are already on complex immunosuppressant regimens, necessitating rigorous monitoring of drug interactions.

The core divergence between our specialties lies in pathophysiology. Cardiology focuses heavily on vasodilation to reduce right ventricular afterload. However, in SLE or MCTD-associated PAH, the initial driver is often profound autoimmunity and vasculitis. We cannot cede control entirely to PAH-targeted drugs during active disease flares; aggressive immunosuppression remains irreplaceable.

Our role is not merely referring patients to cardiology. We must lead early screening and champion the anti-inflammatory cornerstone within the multidisciplinary team to prevent superficial symptom management.

PH Case sharing- 1

林佳凌 醫師 (成大醫院心臟內科)

Pulmonary hypertension is not an uncommon clinical situation. It is most commonly associated with left heart disease or lung disease. We will explore a case presented with acute right heart failure. After initial management, further detailed work-up favored a relatively rare cause of pulmonary hypertension. The presentation will focus on rationale of differential diagnosis. Finally, we will show the case's response to treatment and follow-up condition.

PH Case sharing- 2

王愷君 醫師 (高雄榮總免疫風濕科)

Pulmonary hypertension is a common complication of systemic sclerosis and is associated with substantially increased mortality. Early detection is essential to improve outcomes through timely evaluation and treatment. Management of systemic sclerosis–associated pulmonary hypertension requires multidisciplinary collaboration, integrating rheumatology, cardiology, pulmonology, and specialized pulmonary hypertension care. In this session, we will share representative cases to highlight practical approaches to screening, diagnostic evaluation, and individualized therapy.

肺高壓心臟超音波小學堂

李文煌醫師 (成大醫院心臟內科)

演講摘要：

心臟超音波是篩檢與評估肺高壓 (PH) 的首選非侵入性工具。隨著 2025 年 ASE 指南的發布，以及肺高壓定義下修至平均肺動脈壓 >20 mmHg，超音波的角色更為關鍵。本演講將深入淺出地解析 PH 的超音波評估核心：從如何獲取精準的三尖瓣逆流流速 (TRV) 以評估肺高壓機率，到利用下腔靜脈 (IVC) 正確估算右心房壓力。

除了血流動力學，也將重點探討右心室 (RV) 的適應性變化。課程涵蓋右心結構與功能的量化指標 (如 TAPSE、FAC、RV Strain)，並強調「右心室-肺動脈耦合 (RV-PA coupling)」作為預後評估的重要參數。透過系統性的影像判讀與風險分層，希望能早期診斷出肺高壓的病患，給予後續鑑別診斷一個重要的方向。

鍾昇穎醫師

【現職】

- 高雄長庚醫院助理教授級主治醫師
- 高雄長庚醫院心臟內科講師級主治醫師

【學歷】

- 高雄醫學大學醫學系畢業

【經歷】

- 高雄長庚醫院住院醫師

【專長】

●一般心臟學、心臟超音波、心導管檢查、介入性心導管、周邊動脈阻塞介入性治療、動靜脈瘻管阻塞介入性治療

其他相關專科證書

【會員】

- 中華民國心臟學會
- 台灣內科醫學會

【論文期刊發表】

●Chung SY, Sheu JJ, Lin YJ, Sun CK, Chang LT, Chen YL, Tsai TH, Chen CJ, Yang CH, Hang CL, Leu S, Wu CJ, Lee FY, Yip HK. Outcome of patients with profound cardiogenic shock after cardiopulmonary resuscitation and prompt extracorporeal membrane oxygenation support: A single-center observational study. *Circ J* 2012; 76:1385-92

許鐘元 Chung-Yuan Hsu, M.D.

Education:

成功大學，醫學士，1997年9月－2004年6月

Academic Appointment:

1. 長庚醫學院助理教授
2. 中山大學助理教授

Employment Record:

1. 住院醫師，高雄長庚紀念醫院內科部，2006年7月－2009年6月
2. 總醫師，高雄長庚紀念醫院風濕過敏免疫科，2009年7月－2011年6月
3. 主治醫師，高雄長庚紀念醫院風濕過敏免疫科，2011年7月－至今
4. 科負責人，廈門長庚醫院內科部風濕過敏免疫科，2013年4月－2015年6月
5. 科主任，高雄長庚紀念醫院風濕過敏免疫科，2023年10月－至今
6. 中華民國風濕病醫學會秘書長，2023年－2025年
7. 中華民國風濕病醫學會理事，2026年－至今

Lin, Jia-Ling 林佳凌

Education

2005-2012 M.D., National Cheng Kung University, Tainan, Taiwan

Employment Record

2012-2013 Post-graduate year training, National Cheng Kung University Hospital

2013-2014, 2015-2017 Resident, Department of Internal Medicine,

National Cheng Kung University Hospital, Tainan, Taiwan

2017-2019 Clinical Fellow, Division of Cardiovascular Department,

National Cheng Kung University Hospital, Tainan, Taiwan

2019-2021 Attending Physician, Division of Cardiovascular Department,

National Cheng Kung University Hospital, Tainan, Taiwan

2021-2023 Attending Physician, Division of Cardiovascular Department,

National Cheng Kung University Hospital Dou-Liou Branch, Yunlin, Taiwan

2023- Attending Physician, Division of Cardiovascular Department,

National Cheng Kung University Hospital, Tainan, Taiwan

Board Certification

Adult Cardiologist

Interventional Cardiologist

Intensivist

Professional Affiliation

Taiwan Society of Internal Medicine

Taiwan Society of Cardiology (TSOC)

2022-2024 Member of TSOC Young Physician Working Group

2024-2026 Cross-Discipline Committee

Taiwan Society of Cardiovascular Intervention

Taiwan Society of Critical Care Medicine

Taiwan Society of Heart Failure

2024-2027 Education Committee

KAI CHUN WANG

RHEUMATOLOGIST & CLINICAL IMMUNOLOGIST

Current Position: Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital

Phone: +886-7-3422121 #72056

Email: kcwang@vghks.gov.tw

Address: No.386, Dazhong 1st Rd., Zuoying Dist., Kaohsiung City 813414, Taiwan (R.O.C.) Division of Allergy-Immunology-Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital

EDUCATION

2005-2012 M.D., School of Medicine, National Taiwan University, Taipei, Taiwan

2022- The Doctoral Program of Clinical and Experimental Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan

EMPLOYMENT

Aug. 2013 - Jul. 2014 Postgraduate Year, Taipei Veterans General Hospital

Sep. 2014 - Jul. 2017 Medical Residency, Taipei Veterans General Hospital

Aug. 2017 - Oct. 2019 Chief Residency and Fellowship of Allergy, Immunology and Rheumatology, Taipei Veterans General Hospital

Oct. 2019 - Nov. 2019 Attending physician, Division of Allergy, Immunology and Rheumatology, Department of Medicine, Taipei Veterans General Hospital

Nov. 2019 - Oct. 2021 Attending physician, Department of Medicine, Kaohsiung Veterans General Hospital Pingtung Branch

Nov. 2021 - Attending physician, Division of Allergy-Immunology-Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital

PROFESSIONAL AFFILIATIONS

1. Taiwan Society of Internal Medicine
2. Taiwan College of Rheumatology
3. The Chinese Society of Immunology
4. Taiwan Society of Ultrasound in Medicine